title: Concurrent weekly nedaplatin, external beam radiotherapy and high-dose-rate brachytherapy in patients with FIGO stage IIIb cervical cancer: a comparison with a cohort treated by radiotherapy alone.
abstract: OBJECTIVE
  The aim of this study was to evaluate whether nedaplatin-based concurrent chemoradiotherapy (CCRT) using high-dose-rate intracavitary brachytherapy (HDR-ICBT) is superior to radiotherapy (RT) alone in patients with FIGO stage IIIb cervical cancer.
  
  
  METHODS
  The records of 41 consecutive women treated either with nedaplatin-based CCRT using HDR-ICBT (n = 20) or RT alone (nonrandomized control group, n = 21) for stage IIIb cervical cancer were retrospectively reviewed. The activity and toxicity were compared between the two treatment groups. Progression-free survival (PFS) and overall survival (OS) were the main endpoints.
  
  
  RESULTS
  The 5-year overall survival rates in the CCRT and RT groups were 65 and 33.3%, respectively. The median OS of the CCRT and RT groups were 60 and 29 months, respectively. CCRT was significantly superior to RT alone with regard to PFS (p = 0.0015) and OS (p = 0.0364). The frequency of acute grade 3-4 toxicity was significantly higher in the CCRT group than in the RT group. However, no statistically significant difference was observed with regard to severe late toxicity.
  
  
  CONCLUSIONS
  Nedaplatin-based concurrent chemoradiotherapy was safely performed and significantly improved the prognosis of patients with FIGO stage IIIb cervical cancer. This treatment can be considered as an alternative to cisplatin-based chemoradiotherapy in this patient population.
authors.affiliation: Departments of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Japan.
authors.forename: Seiji
authors.initials: S
authors.lastname: Mabuchi
authors.forename: Hiromi
authors.initials: H
authors.lastname: Ugaki
authors.forename: Fumiaki
authors.initials: F
authors.lastname: Isohashi
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Yoshioka
authors.forename: Kumiko
authors.initials: K
authors.lastname: Temma
authors.forename: Namiko
authors.initials: N
authors.lastname: Yada-Hashimoto
authors.forename: Takashi
authors.initials: T
authors.lastname: Takeda
authors.forename: Toshiya
authors.initials: T
authors.lastname: Yamamoto
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Yoshino
authors.forename: Ryuichi
authors.initials: R
authors.lastname: Nakajima
authors.forename: Chie
authors.initials: C
authors.lastname: Kuragaki
authors.forename: Kenichirou
authors.initials: K
authors.lastname: Morishige
authors.forename: Takayuki
authors.initials: T
authors.lastname: Enomoto
authors.forename: Takehiro
authors.initials: T
authors.lastname: Inoue
authors.forename: Tadashi
authors.initials: T
authors.lastname: Kimura
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001918:Brachytherapy / Q000009:adverse effects; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy; D003131:Combined Modality Therapy / Q000009:adverse effects; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D012189:Retrospective Studies; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; C053989:nedaplatin